Renal tubular dysgenesis due to twin-twin transfusion

Summary

Renal tubular dysgenesis due to twin-twin transfusion (MONDO:0019984) is a disease. A subtype of renal tubular dysgenesis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	renal tubular dysgenesis due to twin-twin transfusion
Mondo ID	MONDO:0019984
Orphanet	97367
ICD-11	122234138
UMLS	C5438872
MedGen	1766862
GARD	0019377
Is cancer (heuristic)	no

Disease family

This is a subtype of renal tubular dysgenesis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › kidney disorder › renal tubular dysgenesis › renal tubular dysgenesis due to twin-twin transfusion

Related subtypes (2): renal tubular dysgenesis of genetic origin, drug-related renal tubular dysgenesis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.